Angelakopoulos H, Hohmann E L
Infectious Disease Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Infect Immun. 2000 Apr;68(4):2135-41. doi: 10.1128/IAI.68.4.2135-2141.2000.
Attenuated Salmonella enterica serovar Typhi has been studied as an oral vaccine vector. Despite success with attenuated S. enterica serovar Typhimurium vectors in animals, early clinical trials of S. enterica serovar Typhi expressing heterologous antigens have shown that few subjects have detectable immune responses to vectored antigens. A previous clinical study of phoP/phoQ-deleted S. enterica serovar Typhi expressing Helicobacter pylori urease from a multicopy plasmid showed that none of eight subjects had detectable immune responses to the vectored antigen. In an attempt to further define the variables important for engendering immune responses to vectored antigens in humans, six volunteers were inoculated with 5 x 10(7) to 8 x 10(7) CFU of phoP/phoQ-deleted S. enterica serovar Typhimurium expressing the same antigen. Two of the six volunteers had fever; none had diarrhea, bacteremia, or other serious side effects. The volunteers were more durably colonized than in previous studies of phoP/phoQ-deleted S. enterica serovar Typhi. Five of the six volunteers seroconverted to S. enterica serovar Typhimurium antigens and had strong evidence of anti-Salmonella mucosal immune responses by enzyme-linked immunospot studies. Three of six (three of five who seroconverted to Salmonella) had immune responses in the most sensitive assay of urease-specific immunoglobulin production by blood mononuclear cells in vitro. One of these had a fourfold or greater increase in end-point immunoglobulin titer in serum versus urease. Attenuated S. enterica serovar Typhimurium appears to be more effective than S. enterica serovar Typhi for engendering immune responses to urease. Data suggest that this may be related to a greater stability of antigen-expressing plasmid in S. enterica serovar Typhimurium and/or prolonged intestinal colonization. Specific factors unique to nontyphoidal salmonellae may also be important for stimulation of the gastrointestinal immune system.
减毒伤寒沙门氏菌已被作为口服疫苗载体进行研究。尽管减毒鼠伤寒沙门氏菌载体在动物实验中取得了成功,但表达异源抗原的伤寒沙门氏菌早期临床试验表明,很少有受试者对载体抗原产生可检测到的免疫反应。之前一项关于从多拷贝质粒表达幽门螺杆菌脲酶的phoP/phoQ缺失伤寒沙门氏菌的临床研究显示,8名受试者中没有一人对载体抗原产生可检测到的免疫反应。为了进一步确定对人类载体抗原产生免疫反应重要的变量,6名志愿者接种了5×10⁷至8×10⁷CFU表达相同抗原的phoP/phoQ缺失鼠伤寒沙门氏菌。6名志愿者中有2人发烧;无人出现腹泻、菌血症或其他严重副作用。与之前对phoP/phoQ缺失伤寒沙门氏菌的研究相比,这些志愿者的定植更持久。6名志愿者中有5人血清转化为鼠伤寒沙门氏菌抗原,通过酶联免疫斑点研究有强有力的证据表明存在抗沙门氏菌黏膜免疫反应。6名志愿者中有3人(血清转化为沙门氏菌的5人中的3人)在体外血液单核细胞产生脲酶特异性免疫球蛋白的最敏感检测中有免疫反应。其中一人血清中针对脲酶的终点免疫球蛋白滴度增加了四倍或更多。减毒鼠伤寒沙门氏菌在产生针对脲酶的免疫反应方面似乎比伤寒沙门氏菌更有效。数据表明,这可能与鼠伤寒沙门氏菌中表达抗原的质粒更稳定和/或肠道定植时间延长有关。非伤寒沙门氏菌特有的特定因素可能对刺激胃肠道免疫系统也很重要。